ClinicalTrials.gg
Active, not recruitingNCT04683549HPV-RICCOUpdated Jan 8, 2024

HPV Serum Level and FDG PET CT in Patients With Cervical Cancer Treated With Radical Radiochemotherapy

An interventional study of HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy in Cervical Cancer, sponsored by The Greater Poland Cancer Centre. Active, not recruiting at 1 site in Poland. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by The Greater Poland Cancer Centre · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2020, registered Dec 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Uterine Cervical Neoplasms with a site in Poland — 6 open to participants now, 10 under way, 3 of them phase 3. Uterine Cervical Neoplasms · Poland.

Enrollment
27th of 27
30 · median 256
Started
2020
with 3 others
No phase
2 of 31
none open now
Registered
17th of 31
by date

Among the 31 studies in Uterine Cervical Neoplasms with a site in Poland, this one is the 27th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2020, is one of 2 with no phase, and was the 17th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

6 of the 31 studies in Uterine Cervical Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Uterine Cervical Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

The main purpose of the study is to describe changes in plasma HPV DNA levels in patients with locally advanced cervical cancer during radical radiochemotherapy (CRT) and to correlate changes with response to treatment. Monitoring of the response to treatment will also be assessed in FDG PET CT imaging.

Read the detailed description

Ninety-five per cent of cervical cancer cases are caused by persistent infections with carcinogenic HPVs. Locally advanced stage IB2 to IVA cervical cancers are treated with definitive chemoradiation therapy (CRT). Despite known clinical prognostic factors of poor treatment outcome such as advanced stage and positive nodal status, we still don't know predictors of relapse.

HPV status will be assessed in the neoplastic tissue and DNA from the blood serum of patients with cervical cancer will be isolated and analyzed by real-time PCR. Plasma HPV DNA would identify patients with residual disease after CRT due to persistent detectable HPV. This would earlier detect high risk patients who would benefit from adjuvant therapy.

While metabolic response in post - therapy FDG PET CT is predictive of survival, there is usually 3 months waiting period time needed to perform this imaging. This pilot study will provide preliminary estimates of the correlation between plasma HPV DNA level, PET finding and clinical outcome in polish cervical cancer patients.

03

Conditions studied

  • Cervical Cancer

Keywords

  • locally advanced cervical cancer
  • HPV
  • radiochemotherapy
  • FDG PET CT
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age Limits: more than 18Y confirmed squamous cell carcinoma, FIGO stage IB-IVA planned for radical radiochemotherapy (ECOG) performance status 0,1,2

Exclusion criteria

Exclusion Criteria:

Patients who have received any anticancer treatment for their cervical cancer. (ECOG) performance status > 2 Other cervical cancer tumor histologies (e.g. small cell, serous) to 18FDG PET-CT Contraindication to radiochemotherapy Known pregnancy or lactating

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    One-Arm HPV serum level and FDG PET CT

    HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy

    Diagnostic Test: HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy

Interventions

  • Diagnostic testHPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy

    Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have: 1. FDG PET Scan before treatment and 3 months after treatment 2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status 3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy, 4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy.

06

What researchers measure

Primary outcomes

  1. local control

    Time frame: 18 months

  2. Response to treatment

    Time frame: 6 months

Secondary outcomes

  1. Progression-free survival

    Time frame: 18 months

  2. Plasma HPV DNA levels

    Time frame: Up to 3 months

07

Study locations

1 site
  • Greater Poland Cancer Centre / Oncological Gynecology Clinic
    Poznan, Greater Poland 61-866, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2022, 23 months.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's 23 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 24, 2020
StartActual
Jun 15, 2020
Primary completionActual
May 31, 2022
CompletionEst.
Jun 30, 2024
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04683549
Lead sponsor
The Greater Poland Cancer Centre
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Jun 15, 2020
Primary completion
May 31, 2022
Completion
Jun 30, 2024 (estimated)
Last update
Jan 8, 2024

Study contacts

Ewa Burchardt, PhD, MD
principal investigator · Oncological Gynecology Clinic / GPCC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion